619 Durvalumab Plus Carboplatin/paclitaxel Followed by Durvalumab ± Olaparib As a First-Line Treatment for Newly Diagnosed Advanced or Recurrent Endometrial Cancer: Results from the Phase III DUO-E/GOG-3041/ENGOT-EN10 Trial
openalex(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined